Llombart-Cussac A - Search Results

1

Clinicopathological and molecular predictors of [¹⁸F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial.

Llombart-Cussac A, Prat A, Pérez-García JM, Mateos J, Pascual T, Escrivà-de-Romani S, Stradella A, Ruiz-Borrego M, de Las Heras BB, Keyaerts M, Galvan P, Brasó-Maristany F, García-Mosquera JJ, Guiot T, Gion M, Sampayo-Cordero M, Di Cosimo S, Pérez-Escuredo J, de Frutos MA, Cortés J, Gebhart G. Llombart-Cussac A, et al. Eur J Nucl Med Mol Imaging. 2024 Jul;51(9):2733-2743. doi: 10.1007/s00259-024-06683-0. Epub 2024 Apr 8. Eur J Nucl Med Mol Imaging. 2024. PMID: 38587643 Free PMC article. Clinical Trial.

2

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.

Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, Dugan M, Borgs M; Letrozole Neo-Adjuvant Breast Cancer Study Group. Eiermann W, et al. Ann Oncol. 2001 Nov;12(11):1527-32. doi: 10.1023/a:1013128213451. Ann Oncol. 2001. PMID: 11822750 Free article. Clinical Trial.

3

Docetaxel chemotherapy induces transverse superficial loss of the nail plate.

Llombart-Cussac A, Pivot X, Spielmann M. Llombart-Cussac A, et al. Arch Dermatol. 1997 Nov;133(11):1466-7. Arch Dermatol. 1997. PMID: 9371043 No abstract available.

4

Sequential taxane and anthracycline-containing neoadjuvant regimens: the sequential order impact.

Thiery-Vuillemin A, Llombart-Cussac A, Chaigneau L, Villanueva C, Bazan F, Montcuquet P, Maisonnette-Escot Y, Sautiere JL, Algros MP, Pivot X. Thiery-Vuillemin A, et al. Breast. 2011 Feb;20(1):46-9. doi: 10.1016/j.breast.2010.07.001. Epub 2010 Aug 7. Breast. 2011. PMID: 20692157 Free article.

5

Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells.

Eritja N, Domingo M, Dosil MA, Mirantes C, Santacana M, Valls J, Llombart-Cussac A, Matias-Guiu X, Dolcet X. Eritja N, et al. Mol Cancer Ther. 2014 Apr;13(4):776-87. doi: 10.1158/1535-7163.MCT-13-0794. Epub 2014 Jan 21. Mol Cancer Ther. 2014. PMID: 24448819

6

Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up.

Zelek L, Llombart-Cussac A, Terrier P, Pivot X, Guinebretiere JM, Le Pechoux C, Tursz T, Rochard F, Spielmann M, Le Cesne A. Zelek L, et al. J Clin Oncol. 2003 Jul 1;21(13):2583-8. doi: 10.1200/JCO.2003.06.080. J Clin Oncol. 2003. PMID: 12829679

7

Validation of the 2001 St Gallen risk categories for node-negative breast cancer using a database from the Spanish Breast Cancer Research Group (GEICAM).

Colomer R, Viñas G, Beltran M, Izquierdo A, Lluch A, Llombart-Cussac A, Alba E, Munárriz B, Martín M; Spanish Breast Cancer Research Group. Colomer R, et al. J Clin Oncol. 2004 Mar 1;22(5):961-2. doi: 10.1200/JCO.2004.99.143. J Clin Oncol. 2004. PMID: 14990656 No abstract available.

8

Pemetrexed in patients with locally advanced or metastatic breast cancer who had received previous anthracycline and taxane treatment: phase II study.

Llombart-Cussac A, Theodoulou M, Rowland K, Clark RS, Nakamura T, Carrasco E, Cruciani G. Llombart-Cussac A, et al. Clin Breast Cancer. 2006 Dec;7(5):380-5. doi: 10.3816/CBC.2006.n.054. Clin Breast Cancer. 2006. PMID: 17239262 Clinical Trial.

9

First-line vinorelbine-mitoxantrone combination in metastatic breast cancer patients relapsing after an adjuvant anthracycline regimen: results of a phase II study.

Llombart-Cussac A, Pivot X, Rhor-Alvarado A, Le Cesne A, Le Chevalier T, Tursz T, Spielmann M. Llombart-Cussac A, et al. Oncology. 1998 Sep-Oct;55(5):384-90. doi: 10.1159/000011883. Oncology. 1998. PMID: 9732214 Clinical Trial.

10

The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile.

Mathieu MC, Rouzier R, Llombart-Cussac A, Sideris L, Koscielny S, Travagli JP, Contesso G, Delaloge S, Spielmann M. Mathieu MC, et al. Eur J Cancer. 2004 Feb;40(3):342-51. doi: 10.1016/j.ejca.2003.08.015. Eur J Cancer. 2004. PMID: 14746851

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

144 results

Search Page

Filters